Here we aim to decipher the underlying mechanisms of the anti-tumor effects of TRP2 polyclonal antibodies elicited by MCMV-TRP2 vaccination through investigating the individual role of the activating FcγRI, FcγRIII and FcγRIV and the different FcγR-expressing immune effector cells. This evidence concerns the gene DCT and neoplasm.